Topical Janus kinase inhibitors: A review of applications in dermatology

Hosking, Anna-Marie; Juhász, Margit; Mesinkovska, Natasha Atanaskova

doi:10.1016/j.jaad.2018.04.018

Cited by 76 publications

(55 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although JAK inhibitors have shown promising results in the treatment of extensive AAs recently, 10 they may be associated with systemic side effects and high cost. Moreover, topical JAK inhibitors have yielded disappointing results so far 37 . Therefore, even in the era of biologics, localized targeted therapy such as EL should be still required to treat AA.…”

Section: Discussionmentioning

confidence: 99%

Excimer laser/light treatment of alopecia areata: A systematic review and meta‐analyses

Lee

Eun

Kim

et al. 2020

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Alopecia areata (AA) is a common cause of non-scarring alopecia caused by a T cell-mediated autoimmune response to hair follicles. 1,2 The worldwide point prevalence of AA is up to 1%, 3-5 and the lifetime risk is reported to be 2% in the United States. 6 Although AA is not a life-threatening condition, it has considerable impacts on the patient's quality of life. 7,8 Glucocorticoids (topical, systemic, or intralesional) have been the traditional mainstay of treatment. Other unapproved treatment modalities include topical immunotherapies with contact sensitizers; and systemic immunosuppressants such as methotrexate, azathioprine, and cyclosporine. 9 Each modality showed various therapeutic response and also has some limitations such as injection-associated pain, skin atrophy, systemic

show abstract

Section: Discussionmentioning

confidence: 99%

Excimer laser/light treatment of alopecia areata: A systematic review and meta‐analyses

Lee

Eun

Kim

et al. 2020

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

show abstract

“…There are meta-analyses that sustain the beneficial anti-inflammatory effects of topical Janus kinase inhibitors in some inflammatory diseases (psoriasis, atopic dermatitis) (31). An other attractive therapy for AD is the topical phosphodiesterase inhibitors that act by reducing the release of proinflammatory cytokines (32).…”

Section: Discussionmentioning

confidence: 99%

Importance of food in the control of inflammation in atopic dermatitis

2020

View full text Add to dashboard Cite

Patients that suffer from inflammatory diseases need to pay special attention to nutrition. For this reason, it is very important to change the approach of both health professionals and food industry specialists. There must be a close collaboration, starting from research, the development phase of foods for special nutrition states. Our primary objective was to identify foods or potential dietary ingredients, which efficacy in the treatment of atopic dermatitis had been scientifically demonstrated in vitro, in vivo and clinically. Furthemore, our perspective is presented regarding the research and development of foods for special nutritional states in atopic dermatitis. The PubMed database was analyzed for the period 2018-2020, as well as the European Legislation regarding the appropriate requirements for the composition and knowledge applicable to foods destined for use in special medical purposes. The search criteria were 'chronic dermatitis', 'atopic dermatitis', 'psoriasis', 'alternative treatments', 'natural treatments', 'complementary treatments', 'treatments for chronic dermatitis'. We also looked for undesirable effects or side effects of the foods included in the research in order to treat atopic dermatitis. The results showed that prebiotics, probiotics and certain plant extracts had a high efficacy in controlling inflammation in atopic dermatitis. The food development research for special nutrition states (atopic dermatitis) involves a multidisciplinary team. We started with the establishment of the general objective and continued with the consultation of the PubMed, EMBASE and other databases, and with the in vitro, preclinical and/or clinical determination of the efficacy of new developed foods, that must be protected with patents. The development of foods for special nutrition states represents a solution for improving the quality of life of atopic dermatitis patients.

show abstract

“…В недавних исследованиях была продемонстрирована эффективность ингибиторов JAK (в первую очередь, ТОФА) не только при псориазе, но и при других дерматологических заболеваниях [57]. Перспективы применения ингибиторов JAK в дерматологии связана в том числе и с возможностью создания топических форм этих препаратов [58]. Атопический дерматит (атопическая экзема) -весьма распространенное заболевание, иммунопатогенез которого связан с Th2-типом иммунного ответа, проявляющегося синтезом ИЛ4, ИЛ5, ИЛ13 [59].…”

Section: таблицаunclassified

“…Развитие заболевания ассоциируется с гиперэкспрессией генов ИФН и цитокинов (ИЛ2 и ИЛ15), сигнализация которых регулируется JAK1 и JAK3. В серии открытых исследований установлена эффективность ТОФА при гнездной алопеции, в том числе у пациентов с сопутствующим псориазом [58]. К другим дерматологическим заболеваниям, при которых изучается возможность использования ингибиторов JAK, относятся витилиго, ладонно-подошвенный пустулез, идиопатическая многоформная эритема, кожная красная волчанка, ДМ [58,63,64], генерализованная морфея с эозинофильным фасциитом [65], кожный саркоидоз [66] и др.…”

Section: таблицаunclassified

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects

Насонов

Лила

2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to the population level – are far from solution. This served as a powerful impetus to the study of new approaches to pharmacotherapy of IIRD, one of which is associated with the use of low-molecular synthetic drugs that inhibit intracellular "signal" molecules-Janus kinase (JAK), the socalled Jakinibs. The current achievements and trends concerning the use of JAK inhibitors in the treatment of IIRD are considered.

show abstract

Topical Janus kinase inhibitors: A review of applications in dermatology

Cited by 76 publications

References 39 publications

Excimer laser/light treatment of alopecia areata: A systematic review and meta‐analyses

Excimer laser/light treatment of alopecia areata: A systematic review and meta‐analyses

Importance of food in the control of inflammation in atopic dermatitis

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects

Contact Info

Product

Resources

About